{"nctId":"NCT02696031","briefTitle":"Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis","startDateStruct":{"date":"2016-04-29","type":"ACTUAL"},"conditions":["Non-radiographic Spondyloarthritis"],"count":555,"armGroups":[{"label":"Secukinumab, 150 mg Load (Core phase)","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]},{"label":"Secukinumab, 150 mg No Load (Core phase)","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]},{"label":"Placebo (Core phase)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Core Phase Responder 150 mg (Extension phase)","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab","Drug: Placebo"]},{"label":"Core Phase Responder 300 mg (Extension phase)","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]},{"label":"Core Phase Non-Responder 300 mg (Extension phase)","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]}],"interventions":[{"name":"Secukinumab","otherNames":["AIN457"]},{"name":"Placebo","otherNames":["AIN457"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or non-pregnant, non-nursing female patients at least 18 years of age\n* Diagnosis of axial spondyloarthritis according to Ankylosing SpondyloArthritis International Society (ASAS) axial spondyloarthritis criteria\n* objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)\n* active axial spondyloarthritis as assessed by total Bath Ankylosing Spondylitis Disease Activity Index \\>=4 cm\n* Spinal pain as measured by Bath Ankylosing Spondylitis Disease Activity Index question #2 ≥ 4 cm (0-10 cm) at baseline\n* Total back pain as measured by Visual Analogue scale ≥ 40 mm (0-100 mm) at baseline\n* Patients should have been on at least 2 different non-steroidal anti-inflammatory drugs with an inadequate response\n* Patients who have been on a Tumor Necrosis Factor (TNF) α inhibitor (not more than one) must have experienced an inadequate response\n\nExclusion Criteria:\n\n* Patients with radiographic evidence for sacroiliitis, grade ≥ 2 bilaterally or grade ≥ 3 unilaterally\n* Inability or unwillingness to undergo MRI\n* Chest X-ray or MRI with evidence of ongoing infectious or malignant process\n* Patients taking high potency opioid analgesics\n* Previous exposure to secukinumab or any other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor\n* Pregnant or nursing (lactating) women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).\n\nASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).\n\nASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).\n\nASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).\n\nASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).\n\nThe ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains. A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society Partial Remission (ASAS PR)","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).\n\nThe ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10. A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Bath Ankylosing Spondylitis Functional Index (BASFI)","description":"The Bath Ankylosing Spondylitis Functional Index (BASFI) is a set of 10 questions designed to determine the degree of functional limitation in those subjects with AS. The ten questions were chosen with a major input from subjects with AS. The first 8 questions consider activities related to functional anatomy. The final 2 questions assess the subjects' ability to cope with everyday life. A 100 mm visual analog scale (VAS) is used to answer the questions. The mean of the ten questions gives the BASFI score - a value between 0 and 10. (0 being no problem and 10 being the worst problem, captured as a continuous visual analog scale (VAS)). A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":"0.202"},{"groupId":"OG001","value":"-1.64","spread":"0.204"},{"groupId":"OG002","value":"-1.01","spread":"0.206"}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Patients to Achieve a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response","description":"The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS. The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline. A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)","description":"The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated assessment tool using 1 through 10 scales (1 indicating \"no problem\" and 10 indicating \" worst problem\"), to characterize six clinical domains (fatigue, spinal pain, joint pain/selling, localized tenderness, morning stiffness duration, morning stiffness severity) pertaining to five major symptoms of Ankylosing Spondylitis (AS). The computed final BASDAI score is a value between 0 and 10 with a higher score indicating worse disease. A higher score on the VAS signifies higher severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.35","spread":"0.201"},{"groupId":"OG001","value":"-2.43","spread":"0.203"},{"groupId":"OG002","value":"-1.46","spread":"0.205"}]}]}]},{"type":"SECONDARY","title":"Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16","description":"The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each \"yes\" response and no points for each \"no\" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is \"at the moment,\" and the measure requires approximately 6 minutes to complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.45","spread":"0.408"},{"groupId":"OG001","value":"-3.62","spread":"0.414"},{"groupId":"OG002","value":"-1.84","spread":"0.421"}]}]}]},{"type":"SECONDARY","title":"Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 52","description":"The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each \"yes\" response and no points for each \"no\" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is \"at the moment,\" and the measure requires approximately 6 minutes to complete.\n\nSummary statistics are presented for participants (n) without intercurrent events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"4.77"},{"groupId":"OG001","value":"-7.6","spread":"5.38"},{"groupId":"OG002","value":"-6.4","spread":"4.64"}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease","description":"Ankylosing Spondylitis Disease Activity Score (ASDAS) - C-reactive protein (CRP) inactive disease criteria are defined as a value below 1.3. Higher score indicates worse symptoms. The formula is: ASDAS-CRP = 0.121 x total back pain + 0.110 x patient global + 0.073 x peripheral pain/swelling + 0.058 x duration of morning stiffness + 0.579 x ln(hsCRP +1)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in High Sensitivity C-reactive Protein","description":"High sensitivity C-reactive protein is measured as a marker of inflammation from blood samples during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"1.078"},{"groupId":"OG001","value":"0.64","spread":"1.079"},{"groupId":"OG002","value":"0.91","spread":"1.080"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form-36 Physical Component Summary (SF-36 PCS)","description":"The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions.\n\nIt consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The eight domains are based on a scale from 0-100 while PCS and MCS are norm-based scores with a mean of 50 and a standard deviation of 10.\n\nHigher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.71","spread":"0.683"},{"groupId":"OG001","value":"5.57","spread":"0.694"},{"groupId":"OG002","value":"2.93","spread":"0.705"}]}]}]},{"type":"SECONDARY","title":"Change in Sacroiliac Joint Edema - Week 16","description":"Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"0.24"},{"groupId":"OG001","value":"-1.03","spread":"0.18"},{"groupId":"OG002","value":"-0.39","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Change in Sacroiliac Joint Edema - Week 52","description":"Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"4.54"},{"groupId":"OG001","value":"-1.9","spread":"3.40"},{"groupId":"OG002","value":"-0.1","spread":"1.97"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":48,"n":543},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Diarrhoea","Arthralgia"]}}}